Lupin Limited has launched its generic Sugammadex Injection in the U.S. in a new step in the company's pharmaceuticals line-up and in line to be released in the country.
The new product is a generic version of Bridion (Sugammadex Injection) which is used in hospitals to reverse the effect of some muscle relaxants during surgical procedures.
The launch enhances Lupin’s strategy of expanding its presence in the competitive US pharmaceutical market, and to support access to affordable, high-quality medicines. Generic versions of branded drugs help in reducing health care costs and increasing treatment accessibility for hospitals and patients.
Sugammadex injection is mainly used to reverse neuromuscular blockade induced by rocuronium bromide and vecuronium bromide, two commonly used muscle relaxants during general anesthesia.
By rapidly reversing muscle relaxation, patients recover normal muscle function after surgery and thus are safer and quicker post-operative recovery.
Lupin’s generic version has been approved by the United States Food and Drug Administration (USFDA) and is expected to provide hospitals with the cost-effective alternatives to the marketed medication without compromising quality, safety or effectiveness in any manner.
The injectable drug will come in various strengths to meet hospital needs. Lupin's injectable product portfolio in the United States is expanding further as demand for affordable generic medicines increases.
Lupin's biggest international market in the US still contributes substantially to the company's overall revenue.
Lupin has consistently expanded its generic drug portfolio over the years from cardiovascular, respiratory, diabetes, infectious diseases and hospital care.
The generic Sugammadex Injection will increase competition in the market and will bring lower treatment costs down to hospitals.
Hospitals are increasingly turning to generic injectables to lower costs of care and to uphold the standard of care.
The launch also reflects Lupin’s continuing investment in research, manufacturing excellence and regulatory compliance.
The company has focused on developing complex generic formulations and injectable products that require advanced manufacturing capabilities and stringent quality controls.
Lupin is steadily growing a broad portfolio of specialty and complex generic medicines globally. The company is currently seeing numerous USFDA approved drugs for the company to add to its existing pipeline and is one of the leading generic drug manufacturers worldwide.
Generic Sugammadex Injection will be available for hospitals to have more flexibility in procurement as well as continuity in supply with the ability to keep up with the supply.
Healthcare providers also want to see more generic options which are affordable to pay for and do not affect treatment outcomes for patients.
With health care systems all over the world focused on cost-effective treatment plans, the launch of generic Sugammadex Injection by Lupin shows the increasing need for high-quality generic medicines in healthcare.
In addition to that, the launch of the new product shows Lupin's commitment to affordable pharmaceutical solutions and how it is expanding its pharmaceutical presence in the global market.
